Four years after riding the shell of a struggling microcap biotech to Nasdaq with $40 million in cash, microRNA player miRagen Therapeutics is facing a reckoning of its own.

After the market close Thursday, miRagen disclosed a flurry of changes at the company: CEO William Marshall has resigned, leaving COO Lee Rauch in charge as the new chief to oversee a “review of strategic alternatives” — often a sign that the board is eager for a sale, although in-licensing and other deals are also on the table.

As Savara’s cystic fibrosis development program comes to an end, so will the CEO Rob Neville’s 12-year reign at the company.

Following him out the door is his co-founder Taneli Jouhikainen, Savara’s president and chief business officer, who’s resigning to “pursue other opportunities.” Matthew Pauls, the former chief of Strongbridge and a member of the board, is stepping in as chairman and interim CEO.

The hunt for the Grail just got a lot easier. In fact, in a few weeks you’ll likely be able to pick up a portion of it on Robin Hood, no coconut horses required.

Grail, the monstrously backed liquid biopsy biotech, has filed for an IPO. No pricing details have been disclosed, but if history is any indicator, the company will have a chance to cap 6 months of booming pandemic-era offerings the way the billion-dollar Dark Knight films would cap the summer blockbuster in their heyday. CEO Hans Bishop has penciled in $100 million for the raise, but that figure has become a standard placeholder until biotechs can gauge exactly how much they can raise.

Civilization Ventures, a California-based VC fund that successfully bet on biotechs Rocket Pharmaceuticals and Singular Bio a few years ago, is bringing forth its next round of investments.

Founded by entrepreneur Shahram Seyedin-Noor, the company has closed a $35 million fundraise and announced Tuesday morning it plans to invest in three areas: diagnostics, synthetic biology and AI-related digital health. The new life sciences capital comes three years after Civilization’s first fund, an $8 million pool that saw Rocket go public through reverse merger and Singular be acquired by medical-genetics company Invitae.

Seven months after Kura Oncology bid farewell with co-founder and chief medical officer Antonio Gualberto, the biotech has found his successor from the ranks of Big Pharma alumni.

With Phase II data in hand for the lead drug, tipifarnib, and a second program almost ready for the clinic, the biotech was looking for someone well versed in targeted therapy development and experienced with regulators, CEO Troy Wilson told Endpoints News.